相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lack of Access to Rifaximin Upon Hospital Discharge Is Frequent and Results in Increased Hospitalizations for Hepatic Encephalopathy
Ann Marie Stoll et al.
ANNALS OF PHARMACOTHERAPY (2023)
Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis
Jian Fu et al.
PLOS ONE (2022)
EASL Clinical Practice Guidelines on the management of hepatic encephalopathyq
Sara Montagnese et al.
JOURNAL OF HEPATOLOGY (2022)
Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States
Michael L. Volk et al.
JOURNAL OF MEDICAL ECONOMICS (2021)
Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes
Robert S. Rahimi et al.
AMERICAN JOURNAL OF MEDICINE (2021)
Patient Perspectives on Short-Course Pharmacotherapy: Barriers and Facilitators to Medication Adherence
LeeAnne B. Sherwin et al.
JOURNAL OF PATIENT EXPERIENCE (2020)
Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)
Sara Montagnese et al.
DIGESTIVE AND LIVER DISEASE (2019)
Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
Mark Hudson et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2019)
Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
Zhida Wang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
Guy Neff et al.
PHARMACOECONOMICS (2018)
Retrospective cross-sectional pilot study of rifaximin dosing for the prevention of recurrent hepatic encephalopathy
Kelsey C. Lyon et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2017)
Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation
Francesca Romana Ponziani et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
An educational tool for the prophylaxis of hepatic encephalopathy
Maria Garrido et al.
BMJ OPEN GASTROENTEROLOGY (2017)
Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy
S. H. Kang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Hospitalizations Due to Cirrhosis: Clinical Aspects in a Large Cohort of Italian Patients and Cost Analysis Report
Marco Di Pascoli et al.
DIGESTIVE DISEASES (2017)
A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis
Ganesh Pantham et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Symptom Domain Groups of the Patient-Reported Outcomes Measurement Information System Tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis
Kavish R. Patidar et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Natural History of Patients Taking Rifaximin-α for Recurrent Hepatic Encephalopathy and Risk of Future Overt Episodes and Mortality: A Post-hoc Analysis of Clinical Trials Data
Christian A. Bannister et al.
CLINICAL THERAPEUTICS (2016)
Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease
Nasir Khokhar et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Trends in Alcoholic Hepatitis-related Hospitalizations, Financial Burden, and Mortality in the United States
Raxitkumar Jinjuvadia et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2015)
Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy
Kevin D. Mullen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases
JOURNAL OF HEPATOLOGY (2014)
A patients' and caregivers' perspective on hepatic encephalopathy
S. Montagnese et al.
METABOLIC BRAIN DISEASE (2012)
The Multi-Dimensional Burden of Cirrhosis and Hepatic Encephalopathy on Patients and Caregivers
Jasmohan S. Bajaj et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Estimates of Statin Discontinuation Rates Are Influenced by Exposure and Outcome Definitions
Harm C. J. Geers et al.
ANNALS OF PHARMACOTHERAPY (2011)
Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells
Andrea Mencarelli et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Rifaximin Treatment in Hepatic Encephalopathy
Nathan M. Bass et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy
Jerome Fichet et al.
JOURNAL OF CRITICAL CARE (2009)
Medication compliance and persistence: Terminology and definitions
Joyce A. Cramer et al.
VALUE IN HEALTH (2008)
Effect of antibiotics, prebiotics and problotics in treatment for hepatic encephalopathy
G Bongaerts et al.
MEDICAL HYPOTHESES (2005)
分享论文
